Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BAP1 mutation + FGFR2 rearrangement

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q) (2)

BAP1 mutation + FGFR2 fusion (1)

FGFR2 underexpression + FGFR3 mutation (1)

IDH1 mutation + FGFR2 fusion (1)

IDH1 mutation + FGFR2 rearrangement (1)

NOTCH1 positive + FGFR2 mutation (1)

PBRM1 mutation + FGFR2 fusion (1)

TP53 mutation + FGFR2 fusion (1)

BAP1 581-17_585del22 + RAD21 amplification (1)

BAP1 R300Gfs*6 + PD-L1 expression (1)

BAP1 deletion + TMB-L + PD-L1 expression (1)

BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion (1)

BAP1 negative + BRCA1 mutation (1)

FGFR2 K660N + TP53 deletion (0)

CAMK2D overexpression + BAP1 deletion (0)

TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q) (2)

BAP1 mutation + FGFR2 fusion (1)

FGFR2 underexpression + FGFR3 mutation (1)

IDH1 mutation + FGFR2 fusion (1)

IDH1 mutation + FGFR2 rearrangement (1)

NOTCH1 positive + FGFR2 mutation (1)

PBRM1 mutation + FGFR2 fusion (1)

TP53 mutation + FGFR2 fusion (1)

BAP1 581-17_585del22 + RAD21 amplification (1)

BAP1 R300Gfs*6 + PD-L1 expression (1)

BAP1 deletion + TMB-L + PD-L1 expression (1)

BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion (1)

BAP1 negative + BRCA1 mutation (1)

FGFR2 K660N + TP53 deletion (0)

CAMK2D overexpression + BAP1 deletion (0)

›

BAP1 mutation + FGFR2 rearrangement

Cholangiocarcinoma

Sensitive: C3 – Early Trials

Sensitive: C3 – Early Trials